Validation of an Abridged Breast Cancer Risk Prediction Model for the General Population.


Journal

Cancer prevention research (Philadelphia, Pa.)
ISSN: 1940-6215
Titre abrégé: Cancer Prev Res (Phila)
Pays: United States
ID NLM: 101479409

Informations de publication

Date de publication:
01 05 2023
Historique:
received: 25 10 2022
revised: 30 01 2023
accepted: 28 02 2023
medline: 2 5 2023
pubmed: 3 3 2023
entrez: 2 3 2023
Statut: ppublish

Résumé

In this prospective population-based cohort study, we show the improved performance of a new risk assessment model compared with a gold-standard model (BCRAT). The classification of at-risk women using this new model highlights the opportunity to improve risk stratification and implement existing clinical risk-reduction interventions.

Identifiants

pubmed: 36862830
pii: 718562
doi: 10.1158/1940-6207.CAPR-22-0460
pmc: PMC10150247
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

281-291

Informations de copyright

©2023 The Authors; Published by the American Association for Cancer Research.

Références

Breast Cancer Res. 2018 Nov 3;20(1):132
pubmed: 30390716
J Clin Oncol. 2019 Nov 20;37(33):3152-3165
pubmed: 31479306
JAMA Oncol. 2021 Jul 01;7(7):1045-1050
pubmed: 34042955
Prev Med. 2019 Dec;129:105834
pubmed: 31494144
N Engl J Med. 2021 Feb 4;384(5):440-451
pubmed: 33471974
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Genet Med. 2017 Jan;19(1):30-35
pubmed: 27171545
Breast Cancer Res. 2021 Feb 15;23(1):22
pubmed: 33588869
Cell Oncol (Dordr). 2011 Apr;34(2):71-88
pubmed: 21336636
J Natl Cancer Inst. 1999 Sep 15;91(18):1541-8
pubmed: 10491430
Genet Med. 2019 Aug;21(8):1708-1718
pubmed: 30643217
PLoS One. 2020 Mar 6;15(3):e0229999
pubmed: 32142536
J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86
pubmed: 2593165
Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):469-473
pubmed: 33335023
Breast Cancer Res Treat. 2023 Apr;198(2):335-347
pubmed: 36749458
PLoS One. 2018 Oct 3;13(10):e0204834
pubmed: 30281645
J Natl Cancer Inst. 2015 May 08;107(7):
pubmed: 25956172
PLoS One. 2021 Jan 22;16(1):e0245375
pubmed: 33481864
J Natl Cancer Inst. 2015 Apr 08;107(5):
pubmed: 25855707
JAMA. 2019 Sep 3;322(9):857-867
pubmed: 31479144
NPJ Breast Cancer. 2021 Jun 17;7(1):78
pubmed: 34140528
J Clin Oncol. 2016 Dec;34(34):4183-4185
pubmed: 27551127
Stat Med. 2004 Apr 15;23(7):1111-30
pubmed: 15057881
N Engl J Med. 2021 Feb 4;384(5):428-439
pubmed: 33471991
Lancet Oncol. 2019 Apr;20(4):504-517
pubmed: 30799262
Am J Epidemiol. 2000 Dec 15;152(12):1154-63
pubmed: 11130621
Breast Cancer Res Treat. 2015 Dec;154(3):583-9
pubmed: 26589314
Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):359-65
pubmed: 26677205
Am J Hum Genet. 2019 Jan 3;104(1):21-34
pubmed: 30554720
BMC Cancer. 2022 Oct 12;22(1):1058
pubmed: 36224549
Int J Epidemiol. 2022 Jan 6;50(6):1897-1911
pubmed: 34999890
Cancer. 2021 Oct 15;127(20):3742-3750
pubmed: 34228814
J Am Med Inform Assoc. 2020 Apr 1;27(4):621-633
pubmed: 32106284
Cancer Prev Res (Phila). 2021 Feb;14(2):175-184
pubmed: 33097489
Am J Hum Genet. 1998 Jan;62(1):145-58
pubmed: 9443863
J Natl Cancer Inst. 2001 Mar 7;93(5):358-66
pubmed: 11238697
Breast Cancer Res Treat. 2019 Jun;175(2):519-523
pubmed: 30796654
Breast Cancer Res Treat. 2016 Oct;159(3):513-25
pubmed: 27565998
Breast Cancer Res. 2015 Dec 01;17(1):147
pubmed: 26627479
J Clin Oncol. 2011 Jun 10;29(17):2327-33
pubmed: 21537036
N Engl J Med. 2005 Jul 21;353(3):229-37
pubmed: 16034008
J Natl Cancer Inst. 2015 Mar 04;107(5):
pubmed: 25745020
BMC Med. 2019 Dec 16;17(1):230
pubmed: 31842878
Breast Cancer Res. 2012 Nov 05;14(6):R144
pubmed: 23127309
Am J Epidemiol. 2017 Nov 1;186(9):1026-1034
pubmed: 28641372
Ann Intern Med. 2012 May 1;156(9):635-48
pubmed: 22547473
Nature. 2018 Oct;562(7726):203-209
pubmed: 30305743
Genet Med. 2022 Jul;24(7):1485-1494
pubmed: 35426792
Lancet. 2001 Oct 27;358(9291):1389-99
pubmed: 11705483
Genet Med. 2020 Nov;22(11):1803-1811
pubmed: 32624571
JAMA Netw Open. 2020 Apr 1;3(4):e203959
pubmed: 32347951
J Med Genet. 2022 Dec;59(12):1196-1205
pubmed: 36162852
PLoS One. 2019 May 31;14(5):e0214311
pubmed: 31150407
Br J Cancer. 2008 Apr 22;98(8):1457-66
pubmed: 18349832
Am J Epidemiol. 2015 Nov 15;182(10):863-7
pubmed: 26520360
Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1187-1194
pubmed: 31015199
BMC Cancer. 2020 Jun 18;20(1):570
pubmed: 32552763
Expert Rev Anticancer Ther. 2009 Jan;9(1):51-60
pubmed: 19105706
NPJ Breast Cancer. 2021 Aug 3;7(1):102
pubmed: 34344894

Auteurs

Erika L Spaeth (EL)

Phenogen Sciences Inc, Charlotte, North Carolina.

Gillian S Dite (GS)

Genetic Technologies Limited, Fitzroy, Victoria, Australia.

John L Hopper (JL)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.

Richard Allman (R)

Genetic Technologies Limited, Fitzroy, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH